Hongrui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongrui Liu has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Minqi Li
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China
21 shared publications Xing Rong
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration, Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration, Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China; Center of Osteoporosis and Bone Mineral Research, Shandong University, Jinan, China
6 shared publicationsYajun Cui
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Shandong University, Jinan, China
6 shared publicationsPanpan Yang
Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, 250021 Jinan, China
5 shared publicationsRuihan Gao
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Shandong University, Jinan, China
4 shared publicationsWeidong Zhang
Department of Bone Metabolism, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration, Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration, Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China; Center of Osteoporosis and Bone Mineral Research, Shandong University, Jinan, China
4 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
IMP2 enhances M2 macrophage polarization via LKB1-AMPK-mediated mitochondrial dynamics and fatty acid β-oxidation to ameliorate diabetic osteoporosis
The online version contains supplementary material available at 10.1007/s00018-026-06093-5.
- 27 February 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessIMP2 enhances M2 macrophage polarization via LKB1-AMPK-mediated mitochondrial dynamics and fatty acid β-oxidation to ameliorate diabetic osteoporosis
The online version contains supplementary material available at 10.1007/s00018-026-06093-5.
- Top Cited PapersOpen Access
- 26 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70754
The Interface of Oral and Brain Health: Current Insights Into the Bidirectional Relationship Between Alzheimer's Disease and Periodontitis
Background: The bidirectional relationship between Alzheimer's disease (AD) and periodontitis highlights a critical interface between oral and brain health, increasingly recognized as a key axis in aging‐related degenerative diseases. This review synthesizes epidemiological, pathological, and mechanistic evidence underpinning their interconnected pathogenesis. Results and Conclusion: Epidemiologically, periodontitis is associated with an increased risk of AD, while AD patients exhibit a higher prevalence of periodontitis, driven by cognitive decline‐impaired oral hygiene and synergistic inflammatory mechanisms. Pathologically, periodontal pathogens (e.g., Porphyromonas gingivalis ) translocate to the brain via hematogenous, trigeminal, or oral‐intestinal pathways, inducing neuroinflammation, β‐amyloid (Aβ) aggregation, and tau hyperphosphorylation through virulence factors like gingipains and LPS. Conversely, AD‐related neurodegeneration disrupts bone homeostasis to aggravate periodontitis via multiple mechanisms: (1) Aβ‐mediated osteoclast activation through RAGE/NF‐κB signaling and suppression of osteoblastogenesis; (2) autonomic nervous system dysregulation, where sympathetic hyperactivity promotes RANKL‐dependent bone resorption; and (3) endocrine dysfunction, including HPA axis hyperactivation (chronic hypercortisolism), sex hormone deficiency, insulin resistance, and growth hormone/IGF‐1 insufficiency, all of which perturb the balance between bone formation and resorption. Aging exacerbates this bidirectional interplay through immunosenescence (e.g., impaired neutrophil phagocytosis, senescent microglia) and inflammaging, creating a pro‐degenerative milieu that amplifies both diseases. Clinical interventions, such as periodontal therapy and microbiota modulation, show promise in reducing systemic inflammation and slowing AD progression, though causal links require validation. Future research must prioritize longitudinal cohort studies, pathogen‐specific mechanistic investigations, and translational strategies targeting the oral‐brain axis to develop preventive interventions for aging populations.
- 26 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70754
Top Cited PapersOpen AccessThe Interface of Oral and Brain Health: Current Insights Into the Bidirectional Relationship Between Alzheimer's Disease and Periodontitis
Background: The bidirectional relationship between Alzheimer's disease (AD) and periodontitis highlights a critical interface between oral and brain health, increasingly recognized as a key axis in aging‐related degenerative diseases. This review synthesizes epidemiological, pathological, and mechanistic evidence underpinning their interconnected pathogenesis. Results and Conclusion: Epidemiologically, periodontitis is associated with an increased risk of AD, while AD patients exhibit a higher prevalence of periodontitis, driven by cognitive decline‐impaired oral hygiene and synergistic inflammatory mechanisms. Pathologically, periodontal pathogens (e.g., Porphyromonas gingivalis ) translocate to the brain via hematogenous, trigeminal, or oral‐intestinal pathways, inducing neuroinflammation, β‐amyloid (Aβ) aggregation, and tau hyperphosphorylation through virulence factors like gingipains and LPS. Conversely, AD‐related neurodegeneration disrupts bone homeostasis to aggravate periodontitis via multiple mechanisms: (1) Aβ‐mediated osteoclast activation through RAGE/NF‐κB signaling and suppression of osteoblastogenesis; (2) autonomic nervous system dysregulation, where sympathetic hyperactivity promotes RANKL‐dependent bone resorption; and (3) endocrine dysfunction, including HPA axis hyperactivation (chronic hypercortisolism), sex hormone deficiency, insulin resistance, and growth hormone/IGF‐1 insufficiency, all of which perturb the balance between bone formation and resorption. Aging exacerbates this bidirectional interplay through immunosenescence (e.g., impaired neutrophil phagocytosis, senescent microglia) and inflammaging, creating a pro‐degenerative milieu that amplifies both diseases. Clinical interventions, such as periodontal therapy and microbiota modulation, show promise in reducing systemic inflammation and slowing AD progression, though causal links require validation. Future research must prioritize longitudinal cohort studies, pathogen‐specific mechanistic investigations, and translational strategies targeting the oral‐brain axis to develop preventive interventions for aging populations.
- Open Access
- 14 January 2026
- Published by Springer Nature in Inflammation
- Vol. 49 (1)
Impaired Mitophagy-Induced Apoptosis of Gingival Fibroblasts Exacerbates Diabetic Periodontitis Via THBS-1/CD36-Dependent Macrophage Activation
Diabetic periodontitis (DPD) is a severe inflammatory complication characterized by accelerated destruction of periodontal tissues and dysregulated immune responses. Gingival fibroblast (GF)-macrophage interactions drive DPD progression, but the mechanisms linking hyperglycemia, mitochondrial dysfunction, and immune activation remain unclear. Single-cell sequencing analysis of diabetic gingival tissues revealed significant apoptotic activation of GFs, closely linked to mitochondrial dysregulation. Inflammation and metabolic stress disrupt mitochondrial quality-control pathways and promote the overproduction of reactive oxygen species, inducing defective mitophagy. Crucially, apoptotic GFs secrete thrombospondin-1 (THBS-1), which binds to the CD36 receptor on the surface of macrophages, triggering NF-κB-mediated M1 polarization and pro-inflammatory cytokine production. Molecular modelling demonstrated a high-affinity interaction between THBS-1 and CD36. Gene silencing of THBS-1 in GFs or CD36 in macrophages effectively inhibited these changes, confirming the specificity of this cellular crosstalk mechanism. These findings together indicate mediation of hyperglycemia-induced mitochondrial dysfunction through the promotion of GF apoptosis and subsequent THBS-1/CD36/NF-κB-signaling-dependent macrophage activation. Thus, enhanced mitophagy and modulation of the THBS-1/CD36 axis are promising therapeutic strategies to break the self-perpetuating cycle of inflammation and tissue destruction in DPD.
- 14 January 2026
- Published by Springer Nature in Inflammation
- Vol. 49 (1)
Open AccessImpaired Mitophagy-Induced Apoptosis of Gingival Fibroblasts Exacerbates Diabetic Periodontitis Via THBS-1/CD36-Dependent Macrophage Activation
Diabetic periodontitis (DPD) is a severe inflammatory complication characterized by accelerated destruction of periodontal tissues and dysregulated immune responses. Gingival fibroblast (GF)-macrophage interactions drive DPD progression, but the mechanisms linking hyperglycemia, mitochondrial dysfunction, and immune activation remain unclear. Single-cell sequencing analysis of diabetic gingival tissues revealed significant apoptotic activation of GFs, closely linked to mitochondrial dysregulation. Inflammation and metabolic stress disrupt mitochondrial quality-control pathways and promote the overproduction of reactive oxygen species, inducing defective mitophagy. Crucially, apoptotic GFs secrete thrombospondin-1 (THBS-1), which binds to the CD36 receptor on the surface of macrophages, triggering NF-κB-mediated M1 polarization and pro-inflammatory cytokine production. Molecular modelling demonstrated a high-affinity interaction between THBS-1 and CD36. Gene silencing of THBS-1 in GFs or CD36 in macrophages effectively inhibited these changes, confirming the specificity of this cellular crosstalk mechanism. These findings together indicate mediation of hyperglycemia-induced mitochondrial dysfunction through the promotion of GF apoptosis and subsequent THBS-1/CD36/NF-κB-signaling-dependent macrophage activation. Thus, enhanced mitophagy and modulation of the THBS-1/CD36 axis are promising therapeutic strategies to break the self-perpetuating cycle of inflammation and tissue destruction in DPD.
- 17 December 2025
- Published by SAGE Publications in Journal of Dental Research
- Vol. 105 (9) , 1174-1185
Senescent CD4 + T Cells Drive Diabetic Periodontitis via JAK-STAT-ROS-p38 MAPK
Diabetic periodontitis (DPD) is recognized as a common complication of diabetes mellitus. It progresses rapidly and causes severe destruction of periodontal tissues. The condition often leads to a poor prognosis for affected patients. CD4 + T lymphocytes—pivotal effector cells in adaptive immunity—play a central role in driving DPD pathogenesis through immunometabolic dysregulation. The functional dynamics and contributions of CD4 + T cells to DPD pathogenesis remain insufficiently investigated. To investigate this, single-cell RNA sequencing data from the gingival tissues of DPD mice in the Gene Expression Omnibus database were analyzed, identifying significant CD4 + T cell senescence in DPD. This finding was experimentally confirmed using a DPD mouse model. Furthermore, through adoptive transfer experiments, we demonstrated that in DPD, senescent CD4 + T cells exacerbate the release of senescence-associated secretory phenotype (SASP). SASP chemokines recruit immune cells, which in turn release additional inflammatory factors, creating a self-amplifying cycle that disrupts the Th17/Treg balance and worsens bone loss. This reveals the pathogenic role of senescent CD4 + T cells, whereas adoptive transfer of normal CD4 + T cells rescues this pathological process. Bioinformatics analysis linked CD4 + T cell senescence to the JAK-STAT and p38 MAPK signaling pathways. Subsequent experimental validation detected upregulated JAK-STAT and p38 MAPK activity in DPD gingival tissues. Pharmacological inhibition of these pathways in vitro markedly reduced CD4 + T cell senescence. Mechanistically, JAK-STAT activation elevated mitochondrial reactive oxygen species (mtROS), subsequently triggering the tumor necrosis factor α (TNF-α)–p38 MAPK axis. This cascade led to p53 upregulation and enhanced cellular senescence. This study clarifies the immunopathological mechanisms underlying CD4 + T cell senescence in DPD, emphasizing the crosstalk between metabolic dysregulation via JAK-STAT-mtROS and inflammatory signaling through TNF-α–p38 MAPK (proinflammatory signaling cascade). These findings provide novel perspectives for developing therapeutic strategies targeting CD4 + T cell senescence in DPD, thereby mitigating inflammatory factor release and inhibiting alveolar bone resorption.
- 17 December 2025
- Published by SAGE Publications in Journal of Dental Research
- Vol. 105 (9) , 1174-1185
Senescent CD4 + T Cells Drive Diabetic Periodontitis via JAK-STAT-ROS-p38 MAPK
Diabetic periodontitis (DPD) is recognized as a common complication of diabetes mellitus. It progresses rapidly and causes severe destruction of periodontal tissues. The condition often leads to a poor prognosis for affected patients. CD4 + T lymphocytes—pivotal effector cells in adaptive immunity—play a central role in driving DPD pathogenesis through immunometabolic dysregulation. The functional dynamics and contributions of CD4 + T cells to DPD pathogenesis remain insufficiently investigated. To investigate this, single-cell RNA sequencing data from the gingival tissues of DPD mice in the Gene Expression Omnibus database were analyzed, identifying significant CD4 + T cell senescence in DPD. This finding was experimentally confirmed using a DPD mouse model. Furthermore, through adoptive transfer experiments, we demonstrated that in DPD, senescent CD4 + T cells exacerbate the release of senescence-associated secretory phenotype (SASP). SASP chemokines recruit immune cells, which in turn release additional inflammatory factors, creating a self-amplifying cycle that disrupts the Th17/Treg balance and worsens bone loss. This reveals the pathogenic role of senescent CD4 + T cells, whereas adoptive transfer of normal CD4 + T cells rescues this pathological process. Bioinformatics analysis linked CD4 + T cell senescence to the JAK-STAT and p38 MAPK signaling pathways. Subsequent experimental validation detected upregulated JAK-STAT and p38 MAPK activity in DPD gingival tissues. Pharmacological inhibition of these pathways in vitro markedly reduced CD4 + T cell senescence. Mechanistically, JAK-STAT activation elevated mitochondrial reactive oxygen species (mtROS), subsequently triggering the tumor necrosis factor α (TNF-α)–p38 MAPK axis. This cascade led to p53 upregulation and enhanced cellular senescence. This study clarifies the immunopathological mechanisms underlying CD4 + T cell senescence in DPD, emphasizing the crosstalk between metabolic dysregulation via JAK-STAT-mtROS and inflammatory signaling through TNF-α–p38 MAPK (proinflammatory signaling cascade). These findings provide novel perspectives for developing therapeutic strategies targeting CD4 + T cell senescence in DPD, thereby mitigating inflammatory factor release and inhibiting alveolar bone resorption.
- Open Access
- 15 October 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 85, 785-803
Risperidone induces osteoporosis and neuropsychiatric treatment resistance via SMPD1-lysosome-mediated ferroptosis: dual rescue by active vitamin D analog ED-71
- 15 October 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 85, 785-803
Open AccessRisperidone induces osteoporosis and neuropsychiatric treatment resistance via SMPD1-lysosome-mediated ferroptosis: dual rescue by active vitamin D analog ED-71
- 4 January 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (1) , 1-18
Immunopathogenesis and immunotherapy of diabetes-associated periodontitis
Objectives This paper aims to review the immunopathogenesis of Diabetes-associated periodontitis (DPD) and to propose a description of the research progress of drugs with potential clinical value from an immunotherapeutic perspective. Materials and methods A comprehensive literature search was conducted in PubMed, MEDLINE, Embase, Web of Science, Scopus and the Cochrane Library. Inclusion criteria were studies on the association between diabetes and periodontitis using the Boolean operator “AND” for association between diabetes and periodontitis, with no time or language restrictions. Search terms included diabetes mellitus, periodontitis, immunopathogenesis, specific immunity, non-specific immunity, flora, estrogen, pharmacological treatment, immunotherapy. Results Alterations in the subgingival flora environment in a hyperglycemic environment elicit an immune response. Overactivity/suppression of nonspecific immune cells and impaired cellular defenses trigger specific immune responses. Epigenetics as well as female hormones also play a role. There is already a small amount of clinical evidence for the role of metronidazole, subantimicrobial doses of doxycycline, minocycline hydrochloride, and metformin in the treatment of DPD. Some preclinical studies have also accumulated experimental evidence for the improved effects of vitamin D3 and other drugs on DPD. Conclusions The development of diabetic periodontitis is immunologically linked to a state of immune imbalance and therefore holds great promise for the use of immunotherapeutic drugs. Clinical significance Immunotherapy with drugs along with periodontal nonsurgical treatment could provide ideas for DPD treatment based on the immunopathogenesis of DPD.
- 4 January 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (1) , 1-18
Immunopathogenesis and immunotherapy of diabetes-associated periodontitis
Objectives This paper aims to review the immunopathogenesis of Diabetes-associated periodontitis (DPD) and to propose a description of the research progress of drugs with potential clinical value from an immunotherapeutic perspective. Materials and methods A comprehensive literature search was conducted in PubMed, MEDLINE, Embase, Web of Science, Scopus and the Cochrane Library. Inclusion criteria were studies on the association between diabetes and periodontitis using the Boolean operator “AND” for association between diabetes and periodontitis, with no time or language restrictions. Search terms included diabetes mellitus, periodontitis, immunopathogenesis, specific immunity, non-specific immunity, flora, estrogen, pharmacological treatment, immunotherapy. Results Alterations in the subgingival flora environment in a hyperglycemic environment elicit an immune response. Overactivity/suppression of nonspecific immune cells and impaired cellular defenses trigger specific immune responses. Epigenetics as well as female hormones also play a role. There is already a small amount of clinical evidence for the role of metronidazole, subantimicrobial doses of doxycycline, minocycline hydrochloride, and metformin in the treatment of DPD. Some preclinical studies have also accumulated experimental evidence for the improved effects of vitamin D3 and other drugs on DPD. Conclusions The development of diabetic periodontitis is immunologically linked to a state of immune imbalance and therefore holds great promise for the use of immunotherapeutic drugs. Clinical significance Immunotherapy with drugs along with periodontal nonsurgical treatment could provide ideas for DPD treatment based on the immunopathogenesis of DPD.
- Open Access
- 15 November 2024
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-18
AGEs impair osteogenesis in orthodontic force-induced periodontal ligament stem cells through the KDM6B/Wnt self-reinforcing loop
Diabetes, occasionally diagnosed in orthodontic patients, can impede orthodontic tooth movement (OTM) by accumulating advanced glycation end products (AGEs) in the periodontium. This accumulation impairs the osteogenic differentiation of periodontal ligament stem cells (PDLSCs) due to alterations in the force-loaded microenvironment, yet the underlying mechanisms remain elusive. Bioinformatics analysis of GSE112122 identified alterations in the mechanical regulation of histone methylation enzyme Lysine Demethylase 6B (KDM6B). OTM models were established in healthy and Nicotinamide/ Streptozotocin-induced type II diabetic rats. The impact of AGEs on mechanically induced osteogenesis and its correlation with KDM6B were evaluated by assessing the therapeutic effects of periodontal ligament injections of the AGEs/RAGE inhibitor FPS-ZM1. To investigate transcriptomic changes, we extracted human PDLSCs, which were subjected to RNA sequencing following the overexpression of KDM6B. Experimental validation further identified potential self-reinforcing loops and their associated antioxidative mechanisms. Mechanical forces upregulated KDM6B expression and function in PDLSCs, modulating extensive downstream osteogenesis-related transcriptional changes. Experiments with AGEs-treated and FPS-ZM1-treated samples demonstrated that AGEs impaired osteogenesis by compromising KDM6B mechanical responsiveness. A positive feedback loop between KDM6B and Wnt pathways was identified, inhibited by AGEs. This loop regulated superoxide dismutase 2 (SOD2), facilitating antioxidative stress and preventing stem cell ageing. This study elucidates a novel mechanism by which AGEs influence the osteogenic process and antioxidative capacity of PDLSCs through the KDM6B/Wnt self-reinforcing loop under orthodontic force. Targeting the AGE/RAGE pathway or enhancing KDM6B may enhance orthodontic treatments for diabetic patients.
- 15 November 2024
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-18
Open AccessAGEs impair osteogenesis in orthodontic force-induced periodontal ligament stem cells through the KDM6B/Wnt self-reinforcing loop
Diabetes, occasionally diagnosed in orthodontic patients, can impede orthodontic tooth movement (OTM) by accumulating advanced glycation end products (AGEs) in the periodontium. This accumulation impairs the osteogenic differentiation of periodontal ligament stem cells (PDLSCs) due to alterations in the force-loaded microenvironment, yet the underlying mechanisms remain elusive. Bioinformatics analysis of GSE112122 identified alterations in the mechanical regulation of histone methylation enzyme Lysine Demethylase 6B (KDM6B). OTM models were established in healthy and Nicotinamide/ Streptozotocin-induced type II diabetic rats. The impact of AGEs on mechanically induced osteogenesis and its correlation with KDM6B were evaluated by assessing the therapeutic effects of periodontal ligament injections of the AGEs/RAGE inhibitor FPS-ZM1. To investigate transcriptomic changes, we extracted human PDLSCs, which were subjected to RNA sequencing following the overexpression of KDM6B. Experimental validation further identified potential self-reinforcing loops and their associated antioxidative mechanisms. Mechanical forces upregulated KDM6B expression and function in PDLSCs, modulating extensive downstream osteogenesis-related transcriptional changes. Experiments with AGEs-treated and FPS-ZM1-treated samples demonstrated that AGEs impaired osteogenesis by compromising KDM6B mechanical responsiveness. A positive feedback loop between KDM6B and Wnt pathways was identified, inhibited by AGEs. This loop regulated superoxide dismutase 2 (SOD2), facilitating antioxidative stress and preventing stem cell ageing. This study elucidates a novel mechanism by which AGEs influence the osteogenic process and antioxidative capacity of PDLSCs through the KDM6B/Wnt self-reinforcing loop under orthodontic force. Targeting the AGE/RAGE pathway or enhancing KDM6B may enhance orthodontic treatments for diabetic patients.
- Open Access
- 16 October 2024
- Published by Wiley in Aging Cell
- Vol. 24 (2) , e14374
Aβ ‐induced excessive mitochondrial fission drives type H blood vessels injury to aggravate bone loss in APP/PS1 mice with Alzheimer's diseases
Alzheimer's diseases (AD) patients suffer from more serious bone loss than cognitively normal subjects at the same age. Type H blood vessels were tightly associated with bone homeostasis. However, few studies have concentrated on bone vascular alteration and its role in AD‐related bone loss. In this study, APP/PS1 mice (4‐ and 8‐month‐old) and age‐matched wild‐type mice were used to assess the bone vascular alteration and its role in AD‐related bone loss. Transmission electron microscopy, immunofluorescence staining and iGPS 1.0 software database were utilized to investigate the molecular mechanism. Mitochondrial division inhibitor (Mdivi‐1) and GSK‐3β inhibitor (LiCl) were used to rescue type H blood vessels injury and verify the molecular mechanism. Our results revealed that APP/PS1 mice exhibited more serious bone blood vessels injury and bone loss during ageing. The bone blood vessel injury, especially in type H blood vessels, was accompanied by impaired vascularized osteogenesis in APP/PS1 mice. Further exploration indicated that beta‐amyloid (Aβ) promoted the apoptosis of vascular endothelial cells (ECs) and resulted in type H blood vessels injury. Mechanistically, Aβ‐induced excessive mitochondrial fission was found to be essential for the apoptosis of ECs. GSK‐3β was identified as a key regulatory target of Aβ‐induced excessive mitochondrial fission and bone loss. The findings delineated that Aβ‐induced excessive mitochondrial fission drives type H blood vessels injury, leading to aggravate bone loss in APP/PS1 mice and GSK‐3β inhibitor emerges as a potential therapeutic strategy.
- 16 October 2024
- Published by Wiley in Aging Cell
- Vol. 24 (2) , e14374
Open AccessAβ ‐induced excessive mitochondrial fission drives type H blood vessels injury to aggravate bone loss in APP/PS1 mice with Alzheimer's diseases
Alzheimer's diseases (AD) patients suffer from more serious bone loss than cognitively normal subjects at the same age. Type H blood vessels were tightly associated with bone homeostasis. However, few studies have concentrated on bone vascular alteration and its role in AD‐related bone loss. In this study, APP/PS1 mice (4‐ and 8‐month‐old) and age‐matched wild‐type mice were used to assess the bone vascular alteration and its role in AD‐related bone loss. Transmission electron microscopy, immunofluorescence staining and iGPS 1.0 software database were utilized to investigate the molecular mechanism. Mitochondrial division inhibitor (Mdivi‐1) and GSK‐3β inhibitor (LiCl) were used to rescue type H blood vessels injury and verify the molecular mechanism. Our results revealed that APP/PS1 mice exhibited more serious bone blood vessels injury and bone loss during ageing. The bone blood vessel injury, especially in type H blood vessels, was accompanied by impaired vascularized osteogenesis in APP/PS1 mice. Further exploration indicated that beta‐amyloid (Aβ) promoted the apoptosis of vascular endothelial cells (ECs) and resulted in type H blood vessels injury. Mechanistically, Aβ‐induced excessive mitochondrial fission was found to be essential for the apoptosis of ECs. GSK‐3β was identified as a key regulatory target of Aβ‐induced excessive mitochondrial fission and bone loss. The findings delineated that Aβ‐induced excessive mitochondrial fission drives type H blood vessels injury, leading to aggravate bone loss in APP/PS1 mice and GSK‐3β inhibitor emerges as a potential therapeutic strategy.